Field evaluations of safety and efficacy of an Australian Marek's disease vaccine.

OBJECTIVE: To demonstrate the safety and efficacy of the Marek's Disease Virus-1 vaccine (strain BH 16) from field studies in comparison with the CVI 988 Rispens vaccine currently available in Australia. STUDY DESIGN: A small field trial was carried out on nine breeder flocks and a larger trial on 21 breeder flocks. All chickens were obtained from a commercial hatchery and each was vaccinated at hatch with cell-associated Herpes Virus of Turkeys vaccine. A group of chickens vaccinated with BH 16 vaccine was placed in one shed per property and the remainder were vaccinated with the Rispens vaccine and placed in the remaining sheds. At 25, 30, 35, and 40 weeks after hatch, the field veterinarian or farm manager examined all birds dying on two consecutive days in the designated placement sheds. RESULTS: In the small trial there was a significantly lower incidence of MD in birds vaccinated with the MDV-1 vaccine compared with the Rispens vaccine (P < 0.001). In a larger trial there was no difference in the incidence of MD between the treatment groups, due possibly to a lower rate of natural challenge. Egg production results and average weekly mortality results for both groups were similar. CONCLUSION: The present study describes an attenuated type 1 MD vaccine which is at least equivalent to a vaccine derived from the CVI 988 Rispens strain in terms of safety and efficacy when used in combination with HVT vaccine.

Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.

OBJECTIVE: To develop a serotype 1 Marek's disease (MD) vaccine from a very virulent MDV (vvMDV) pathotype and demonstrate safety and efficacy against early challenge with very virulent field strains in the presence of maternal antibody. STUDY DESIGN: Strain BH 16 was isolated and attenuated by serial cell culture passage. One of two cloned passages was selected for vaccine development following early laboratory-scale protection trials in commercial birds. Comparative protection trials were carded out on the BH 16 vaccine and on a CVI 988 Rispens vaccine using commercial and SPF chickens. Challenge viruses used were either a low passage strain BH 16 virus, the Woodlands No. 1 strain or MPF 57 strain of MDV. The BH 16 vaccine was back-passaged in SPF chickens six times and virus recovered from the final passage and the original vaccine virus were tested for safety. The immunosuppressive potential of the BH 16 and Rispens vaccines was also assessed in parallel. RESULTS: The BH 16 and Rispens vaccines induced comparable levels of protection when used as monovalent or multivalent vaccines, although protection achieved with the monovalent vaccines was lower. No gross tumour formation was evident in any birds receiving the BH 16 vaccine or bird-passaged virus, although microscopic lesions were present in 2/12 birds that received the bird-passaged virus. In tests for immunosuppression, there was no histological evidence of damage to either the bursa of Fabricius or the thymus. CONCLUSION: The BH 16 vaccine was shown to be safe and at least as protective as the Rispens vaccine against three highly virulent MD challenge viruses.

Vaccination and challenge studies with psittacine beak and feather disease virus.

Psittacine beak and feather disease virus (PBFDV) was administered to adult galahs (Eolophus roseicapillus) by mouth or by intramuscular injection. Concentration of PBFDV antibodies in serum and excretion of PBFDV were monitored by haemagglutination inhibition (HI) and haemagglutination (HA) respectively. After oral administration, 17 of 18 galahs remained clinically normal and a small rise in antibody titre was detected in 3 of 18 birds. After intramuscular administration, antibody was detected in all birds. PBFDV was not detected in the feather dander of birds in either group. One bird developed diarrhoea and high faecal HA titres within 4 days of oral administration and then died. Adult and nestling cockatoos were vaccinated with an experimental inactivated double-oil emulsion vaccine. PBFDV antibody responses are comparable to those induced by a primary-oil emulsion vaccination regimen using Freund's adjuvants. Both vaccines protected nestlings. Three sibling wild-caught sulphur-crested cockatoos were vaccinated but died of PBFD before experimental challenge despite antibody responses in all birds. Unvaccinated control chicks developed acute PBFD within 4 weeks of challenge, probably from PBFDV-induced hepatitis since high concentrations of PBFDV were detected in their livers.

Biological characterisation of Australian isolates of chicken anaemia agent.

Three Australian isolates of chicken anaemia agent (CAA) resisted treatment at 70 degrees C for 5 min and chloroform treatment. Although minor antigenic differences were detected using monoclonal antibodies to CAA, the Australian isolates were indistinguishable from the reference Cux-1 and Gifu-1 isolates in cross-immunofluorescence and cross-neutralisation tests employing polyclonal chicken antiserums. The Australian viruses were pathogenic for intramuscularly inoculated 1-day-old SPF chicks, but were less pathogenic for 7-day-old chicks. Thus the Australian isolates of CAA did not differ significantly in these properties from previously characterised CAA isolates from other continents.

Isolation of haemagglutinating adeno-like virus related to virus 127 from an Australian poultry flock with an egg drop syndrome.

An egg drop syndrome within Australian broiler poultry is described. The syndrome was characterised by delayed onset of laying, a lower peak in egg production and a drop in egg production shortly after reaching peak production. Antibody to virus 127 was detected in 102 of 106 fowl serums tested. Two haemagglutinating viruses were isolated from one affected flock and one was subjected to further study. It was adenovirus-like on electron-microscopic examination and haemagglutination was not inhibited by a specific antiserum to Newcastle disease virus. An antiserum was raised in White Leghorn fowl against the isolate and this antiserum was found to cross-react with virus 127, a prototype virus of Egg Drop Syndrome 76.